细胞重编程可通过调控细胞命运，诱导获得适用于临床治疗的目标细胞类型，开辟了再生医学新的路径。2006年，日本科学家山中伸弥（Shinya Yamanaka）借助病毒载体将Oct4、Sox2、Klf4和c-Myc四个转录因子（OSKM，即“山中因子”）导入成体细胞，将其重编程为诱导多能干细胞（iPS细胞），是生命科学研究里程碑式的突破。

A burgeoning field is launching its first clinical trial to find out whether dialing back cell development can safely refresh ...

The field of partial reprogramming is transitioning from successful mouse studies to its first human clinical trials. At the heart of this experiment lies the discovery of Yamanaka ...

Scientists at Life Biosciences are preparing to begin testing partial reprogramming in people. It will mark the first time ...

For the roughly 80 million people worldwide living with glaucoma, daily life often means watching the world slowly close in.

Zhou’s study, "TBX20 improves contractility and mitochondrial function during direct human cardiac reprogramming," was recently published in Circulation. The most common cause of death worldwide is ...

The company described the round as fully subscribed and said the cash should keep operations running into the second half of ...

Peer-reviewed discovery platform and data in PNAS show that single transcription factor modulation reverses aging-associated gene expression and restores healthy cellular and tissue function in models ...

Ageing reversal may be closer than we think – scientists have begun human trials to test anti-ageing methods.